ANI Pharmaceuticals vs Royalty Pharma
ANIP and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIP and RPRX compare
Royalty Pharma is the larger company, worth 23 times as much as ANI Pharmaceuticals ($38.6B against $1.7B).
On earnings, ANI Pharmaceuticals is cheaper: it trades at 15.3× trailing earnings, against 38.2× for Royalty Pharma.
ANI Pharmaceuticals grew revenue faster over the last twelve months (30.9% versus 10.0% for Royalty Pharma).
Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 32.1% compared with 11.1% at ANI Pharmaceuticals.
Royalty Pharma pays a dividend yielding 1.4%; ANI Pharmaceuticals does not pay one.
ANI Pharmaceuticals scores higher on the StockData Score (13 against 8 for Royalty Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIP | RPRX |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $38.6B |
| Share price | $72.00 | $67.18 |
| Change, 1 year | −21.9% | 83.2% |
| Change, 5 years | 43.9% | 70.0% |
| Beta (5Y) | 0.59 | 0.41 |
| Employees | 970 | 100 |
| StockData Score | ||
| Total score | 13 (better) | 8 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 15.3× (better) | 38.2× |
| P/S | 1.7× (better) | 15.2× |
| P/B | 2.8× | – |
| EV/EBITDA | 6.8× (better) | 32.9× |
| P/FCF | 9.6× | – |
| PEG | – | 0.24 |
| FCF yield | 10.5% | – |
| Fair value | $113.03 | $45.40 |
| Margin of safety | 36.3% (better) | −48.0% |
| Growth | ||
| Revenue growth (TTM) | 30.9% (better) | 10.0% |
| Revenue growth, 5Y average | 33.5% (better) | 2.3% |
| Net income growth (TTM) | – | −20.4% |
| EPS growth (TTM) | – | −19.3% |
| EPS growth, 5Y average | – | 6.2% |
| Profitability | ||
| Gross margin | 60.4% | – |
| Operating margin | 15.4% | 59.6% (better) |
| Net margin | 11.1% | 32.1% (better) |
| FCF margin | 17.7% | – |
| Return on equity | 21.0% | – |
| Return on invested capital | 21.3% | – |
| Financial health | ||
| Debt / equity | 0.50 | – |
| Net debt / EBITDA | −0.25 | 5.37 (better) |
| Interest coverage | 4.8× (better) | 4.2× |
| Current ratio | 2.91 (better) | 2.80 |
| Altman Z-score | 2.56 | 2.93 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.4% |
| Payout ratio | 0.32% | – |
| Buyback yield | 1.3% (better) | 0.83% |
| Shareholder yield | 1.3% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 100% | 63.8% |
| Held by insiders | 12.3% | 22.6% |
| Insider net buying, 12 months | −$15.0M (better) | −$92.6M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 17.3% | 2.9% |
Go deeper
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.